Literature DB >> 30765852

Albuminuria: a target for clinical trials in kidney disease?

Richard J Glassock1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30765852     DOI： 10.1038/s41581-019-0123-x

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  2 in total

1.  Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Authors:  Aliza Thompson; Kevin Carroll; Lesley A Inker; Jürgen Floege; Vlado Perkovic; Sonia Boyer-Suavet; Rupert W Major; Judith I Schimpf; Jonathan Barratt; Daniel C Cattran; Barbara S Gillespie; Annamaria Kausz; Alex W Mercer; Heather N Reich; Brad H Rovin; Melissa West; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-11       Impact factor: 8.237

Review 2.  Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease.

Authors:  Paolo Cravedi; Giuseppe Remuzzi
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335
  2 in total
  1 in total

Review 1.  Therapeutic trials in adult FSGS: lessons learned and the road forward.

Authors:  An S De Vriese; Jack F Wetzels; Richard J Glassock; Sanjeev Sethi; Fernando C Fervenza
Journal:  Nat Rev Nephrol       Date:  2021-05-20       Impact factor: 28.314
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.